The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent License to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Document
Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities
The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent L...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 38707
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities,” thefederalregister.org (August 7, 2018), https://thefederalregister.org/documents/2018-16836/prospective-grant-of-exclusive-patent-license-treatment-of-type-i-diabetes-and-its-comorbidities.